Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.27.3 (RNase T1)
 1,228 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The RNA of a replication-defective (rd) mutant, isolated from stocks of nondefective (nd) Schmidt-Ruppin Rous sarcoma virus of subgroup A (SR-A) and termed SR-N8, was compared to the RNAs of SR-A, of a transformation-defective derivative of SR-A (td SR-A) and of rd Bryan Rous sarcoma virus, RSV (minus). The molecular mass of the 30-40S species of SR-N8 RNA was estimated to be 21% (congruent to 7.5 to 8 times 10-5 daltons) smaller than that of SR-A by (i) electrophoresis in polyacrylamide gels and (ii) analyses of RNA complexity based on RNase T1-resistant oligonucleotides. ST-N8 shares probably all (=14) of its large RNase T1-resistant oligonucleotides with the RNA of SR-A as judged from the chromatographic distribution and the RNase A-resistant fragments obtained from RNase T1-resistant oligonucleotides. However, SR-N8 RNA lacked six large oligonucleotides which were present in the RNAs of SR-A and td SR-A. Conversely, the RNAs of SR-A, and of SR-N8 contained two oligonucleotides not found in td SR-A. The RNA of SR-N8 was found to differ from that of RSV (minus) in its electrophoretic mobility and its fingerprint pattern. It is concluded that the RNA of SR-N8 was generated by a deletion of SR-A. The extent of this deletion is compatible with the notion that the genetic information for the large viral envelope glycoprotein (molecular mass = 70,000-85,000 daltons) has been lost from the RNA of SR-A to yield SR-N8 RNA. From a comparison of td and rd deletion mutants, it appears that loss of different functions corresponds to the absence of different oligonucleotides in their RNA.
 ...
PMID:RNA of replication-defective strains of Rous sarcoma virus. 16 14

An intracellular assay for viral envelope glycoprotein (env) messenger was employed to analyze the RNA from virus particles of Rous-associated virus type 2. For this assay RNA was microinjected into cells infected by the env-deficient Bryan strain of Rous sarcoma virus [RSV(-) cells]. Only when the injected RNA could be translated by the recipient cells to produce viral envelope glycoprotein was the env deficiency of the RSV(-) cells complemented, enabling them to release focus-forming virus. RNA in a 21S size fraction from the Rous-associated virus particle promoted the release of numerous focus-forming virus from RSV(-) cells, whereas the major 35S virion RNA species was inactive. The env messenger activity sedimented as a sharp peak with high specific activity. RNase T1-generated fragments of virion 35S RNA were unable to promote the release of infectious virus from RSV(-) cells. Consequently, the active molecule was most likely to be env messenger which had been encapsulated by the virus particle from the cytoplasm of infected cells. Approximately 95% of the env messenger within the virion was associated with the virion high-molecular-weight RNA complex. The temperature required to dissociate env messenger from the high-molecular-weight complex was indistinguishable from the temperature required to disrupt the complex itself. Virion high-molecular-weight RNA that was associated with env messenger sedimented slightly more rapidly than the bulk virion RNA; this was the strongest evidence that the 21S messenger had been encapsulated directly from the infected cells. These data are considered along with a related observation [concerning the prolonged expression of env messenger after injection into RSV(-) cells] to raise the possibility that virus-encapsulated env messenger can become expressed within subsequently infected cells.
 ...
PMID:Messenger activity of virion RNA for avian leukosis viral envelope glycoprotein. 22 82

Previous genetic and biochemical studies led to the identification of two large RNase T1-resistant oligonucleotides, designated the G(IX) (+) and G(IX) (-) oligonucleotides, whose presence in the genomes of closely related murine leukemia viruses is mutually exclusive and predictive of two properties of the viral envelope glycoprotein gp70. Viruses harboring the G(IX) (+) oligonucleotide induce expression of the gp70-associated antigen G(IX) and possess gp70s with more rapid electrophoretic mobility on sodium dodecyl sulfate/polyacrylamide gels than viruses that possess the G(IX) (-) oligonucleotide. The latter viruses fail to induce G(IX) on infected fibroblasts. The G(IX) (+) and G(IX) (-) oligonucleotides lie in corresponding positions in the 3' third of the oligonucleotide maps of their respective viruses. We have determined the nucleotide sequences of the G(IX) (+) and G(IX) (-) oligonucleotides. The sequence of the G(IX) (-) oligonucleotide is U-A-U-C-U-C-A-A-C-C-A-C-C-A-U-A-C-U-U-A-A-C-C-U-C-A-C-C-A-C-[unk]-G, and the sequence of the G(IX) (+) oligonucleotide is U-A-U-C-U-C-A-A-C-C-A-C-C-A-U-A-C-U-U-G. Thus, a single base change could result in the interconversion of the two oligonucleotides. Consideration of the amino acids specified by the two oligonucleotides suggests that this single base difference may result in the presence of an additional oligosaccharide chain in the gp70s of the G(IX) (-) viruses. Evidence supporting this prediction has been obtained by M. R. Rosner, J.-S. Tung, E. Fleissner, and P. W. Robbins (personal communication). It is entirely possible that the single nucleotide change that apparently results in a different electrophoretic mobility of the gp70s of the G(IX) (+) and G(IX) (-) viruses is also responsible for the presence or absence of the G(IX) antigenic determinant; however, the validity of this possibility awaits further investigation.
 ...
PMID:Nucleotide sequences associated with differences in electrophoretic mobility of envelope glycoprotein gp70 and with GIX antigen phenotype of certain murine leukemia viruses. 615 37

Chicken myeloblasts transformed by avian myeloblastosis virus (AMV) in the absence of nondefective helper virus (termed nonproducer cells) were found to release a defective virus particle (DVP) that contains avian tumor viral gag proteins but lacks envelope glycoprotein and a DNA polymerase. Nonproducer cells contain a Pr76 gag precursor protein and also a protein that is indistinguishable from the Pr180 gag-pol protein of nondefective viruses. The RNA of the DVP is 7.5 kilobases (kb) long and is 0.7 kb shorter than the 8.2-kb RNAs of the helper viruses of AMV, MAV-1 and MAV-2. Comparisons based on RNA.cDNA hybridization and mapping of RNase T1-resistant oligonucleotides indicated that DVP RNA shares with MAV RNAs nearly isogenic 5'-terminal gag and pol-related sequences of 5.3 kb and a 3'-terminal c-region of 0.7 kb that is different from that found in other avian tumor viruses. Adjacent to the c-region, DVP RNA contains a contiguous specific sequence of 1.5 kb defined by 14 specific oligonucleotides. Except for two of these oligonucleotides that map at its 5' end, this sequence is unrelated to any sequences of nondefective avian tumor viruses of four different envelope subgroups as well as to the specific sequences of fibroblast-transforming avian acute leukemia and sarcoma viruses of four different RNA subgroups. The specific sequence of the DVP RNA is present in infectious stocks of AMV from this and other laboratories in an AMV-transformed myeloblast line from another laboratory, and it is about 70% related to nucleotide sequences of E26 virus, an independent isolate of an AMV-like virus. Preliminary experiments show DVP to be leukemogenic if fused into susceptible cells in the presence of helper virus. We conclude that DVP RNA is the leukemogenic component of infectious AMV and that its specific sequence, termed AMV, may carry genetic information for oncogenicity. Thus we have found here a transformation-specific RNA sequence, unrelated to helper virus, in a highly oncogenic virus that does not transform fibroblasts.
 ...
PMID:Genetic structure of avian myeloblastosis virus, released from transformed myeloblasts as a defective virus particle. 615 39

The GIX antigen, which is expressed on the surface of thymocytes of certain mouse strains, is an antigenic determinant of the major envelope glycoprotein of murine leukemia virus (gp70). Although GIX is expressed in some mouse strains that appear to be free of virus, the antigen can also be induced in GIX- mice by infection with particular murine leukemia viruses (termed GIX+). We have investigated the envelope gene products from two closely related viruses that differ in their GIX phenotype. Analysis of the envelope protein precursors by polyacrylamide gel electrophoresis and endoglycosidase treatment indicated that the GIX+ viral protein contained six oligosaccharide chains, whereas the GIX- viral protein contained seven. The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus. No differences between the apparent molecular weights of the nonglycosylated product of the envelope gene (p15E) were detected. These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70). Recent nucleotide sequence analyses of selected RNase T1 oligonucleotides from the genomes of viruses that differ in GIX phenotype have similarly suggested that there may be a correlation between the GIX- phenotype and an extra glycosylation site [Donis-Keller, H., Rommelaere, J., Ellis, R. W. & Hopkins, N. (1980) Proc. Natl. Acad. Sci. USA 77, 1642-1645]. The results of these two different approaches raise the possibility that the presence of an additional oligosaccharide chain on gp70 may, either directly or indirectly, mask the expression of the GIX antigen on the surfaces of thymocytes and virus-infected cells.
 ...
PMID:Relationship of GIX antigen expression to the glycosylation of murine leukemia virus glycoprotein. 693 56